Biocon Ltd

Biocon Ltd

Biocon has entered into a global patent settlement and license agreement with Genentech, securing earliest licensed launch dates for its biosimilar Pebrilzo (bPertuzumab) in various regions, including the European Union, the US, and other countries.

Biocon Ltd

Biocon Ltd has submitted a certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018, confirming the dematerialization of securities for the quarter ended September 30, 2026.

Biocon Ltd

Biocon Ltd has received an Order-In-Original from the Office of the Assistant Commissioner (ST) Atchuthapuram circle, Visakhapatnam-2, Lankelapalem, Anakapalli Dist, Andhra Pradesh, confirming a demand of Goods and Service tax of Rs. 1,85,28,762/-, interest of Rs. 1,17,59,033/- and penalty of Rs. 18,52,476/- for non-submission of Special Economic Zone (SEZ) endorsement documents, improper claim of Input Service Distribution credits, and input tax reversed under temporary reversal instead of permanent reversal.

Biocon Ltd

Biocon Ltd has granted 94,60,232 stock options to eligible employees under the Biocon Unity Long Term Incentive Plan 2026, with an exercise price of Rs. 5/- per stock option.

Biocon Ltd

Biocon Ltd has announced the closure of its trading window from October 1, 2026, until 48 hours after the declaration of its financial results for the quarter and half year ending September 30, 2026.

Biocon Ltd

Biocon Ltd has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA), UK for its new drug product fill finish unit for Semglee (insulin glargine) at its insulin manufacturing facility in Malaysia.

Biocon Ltd

Biocon Ltd informed the stock exchanges about the scheduled meetings with analysts/institutional investors, as per Regulation 30(6) of the SEBI Listing Regulations. The meetings will be held virtually on September 4, 2026, and the company will not disclose any unpublished price sensitive information.

Biocon Ltd

Biocon Ltd has remitted the final dividend for the FY 2025-26, with a dividend of ₹ 0.50 per equity share.

Biocon Ltd

Biocon Ltd has received revised disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Mylan Inc. regarding the disposal of 9,19,67,019 shares of Biocon Ltd, representing 5.64% of the total share capital.

Biocon Ltd

Biocon Ltd announced marketing approval for its pegfilgrastim biosimilar from Japan's Ministry of Health, Labour and Welfare (MHLW). The product, a biosimilar to Neulasta, is developed and manufactured by Biocon Biologics Ltd, a wholly-owned subsidiary of Biocon Ltd.

Biocon Ltd

Biocon Ltd has received supplemental U.S. FDA approval for Yesintek® (ustekinumab-kfce) single-dose prefilled autoinjector, expanding its immunology portfolio in the United States.

Biocon Ltd

Biocon Ltd has scheduled a meeting with analysts/institutional investors as part of the Motilal Oswal 22nd Annual Global Investor Conference on August 17, 2026, in Mumbai. The meeting is subject to change due to exigencies. The company will not disclose any unpublished price-sensitive information during the meeting.

Biocon Ltd

Biocon Ltd has released the transcript of its Q1 FY27 earnings call, where the management team discussed the company's performance and future prospects, highlighting its strategic and financial strength, integration of biosimilars and generics businesses, and opportunities in the North American market.

Biocon Ltd

Biocon Ltd's 48th AGM was held through video conferencing, with voting results and Scrutinizer's report available on the company's website. The AGM approved the audited financial statements, declared a 10% final dividend, and appointed Eric Vivek Mazumdar as a director.

Biocon Ltd

Biocon Ltd has announced an investor meet with analysts and institutional investors on August 12, 2026, as part of Emkay Confluence 2026 Group Virtual. The company will not disclose any unpublished price sensitive information during the meeting.

Biocon Ltd

Biocon Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 43,360 million, profit before tax at Rs. 1,276 million, and profit attributable to shareholders at Rs. 1,411 million.

Biocon Ltd

Biocon Ltd has announced changes in its directorate and statutory auditors at its 48th Annual General Meeting (AGM). Mr. Eric Vivek Mazumdar has been re-appointed as a director, S.R. Batliboi & Associates LLP has been appointed as the new statutory auditors, and Mr. Nicholas Robert Haggar has retired as an independent director.

Biocon Ltd

Biocon Ltd has announced the completion of tenure of its Statutory Auditors, B S R & Co. LLP, and the appointment of S.R. Batliboi & Associates LLP as the new Statutory Auditors for a term of 5 years. Additionally, Mr. Eric Vivek Mazumdar has been re-appointed as Director liable to retire by rotation, and Mr. Nicholas Robert Haggar has retired as an Independent Director upon completion of his term.

Biocon Ltd

Biocon Ltd has announced the appointment of new statutory auditors, S.R. Batliboi & Associates LLP, and the re-appointment of Mr. Eric Vivek Mazumdar as a director. The changes were made at the 48th Annual General Meeting of the company.

Biocon Ltd

Biocon Ltd has announced changes in its directorate and statutory auditors at its 48th Annual General Meeting (AGM). Mr. Eric Vivek Mazumdar has been re-appointed as a director, S.R. Batliboi & Associates LLP has been appointed as the new statutory auditors, and Mr. Nicholas Robert Haggar has retired as an independent director.